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Introduction
In just a few years the Milan Breast Cancer Conference
(the 5th of which was held from 11 to 13 June this year)
has become an important forum at which advances in
breast cancer research and patient care are reviewed in a
multidisciplinary manner. More than 850 physicians
(breast surgeons, epidemiologists, clinical oncologists,
radiotherapists, pathologists, radiologists) from nearly
55 countries attended the meeting.
The conference was guided to a successful conclusion by
the experience of the chairmen Dr Umberto Veronessi and
Dr Aaron Goldhirsch. This year the European Institute of
Oncology Award was given to Dr David Page, Professor
at Vanderbilt University Medical School, who gave an
excellent lecture outlining the importance of ductal carci-
noma in situ as a local precursor of invasive cancer, and
the lesions related to in situ staging.
Prevention and detection in high risk women
Management of high risk women is a major topic. There-
fore, the first section of the conference was dedicated to
prevention and detection. The main points were summa-
rized in a plenary session. Jack Cuzick (Imperial Cancer
Research, UK) gave an overview of the risk factors, which
can be divided into four groups: family history/genetic;
reproductive/hormonal; proliferative benign breast
disease; and mammographic density. Less is known about
the possible interactions between these factors. However,
a computer program able to synthesize the factors into an
individual risk profile could conduct an assessment.
Following this broad definition of high risk, Judy Garber
(Dana Faber Cancer Institute, Boston, MA, USA) showed
that BRCA mutations are the cause of breast cancer in
only 5–10% of the total cases. In addition, BRCA
mutation carriers have a 40–60% risk for developing
contralateral breast cancer. Julian Peto (Institute of
Cancer Research, Sutton, UK) emphasized the impor-
tance of reproductive factors in breast cancer.
In chemoprevention Andrea Decensi (European Institute
of Oncology) and Lawrence Wickerham (Associate Chair-
man of the National Surgical Adjuvant Breast and Bowel
Project) showed that the use of tamoxifen can reduce the
incidence of oestrogen receptor (ER) positive breast
cancer by up to 50%; however, the effect of tamoxifen in
ER negative breast cancer is unknown. The dosage of
tamoxifen, and the concomitant use of hormone replace-
ment therapy and tamoxifen 5mg/day will be evaluated in
the Hormone Replacement Therapy and Tamoxifen (HOT)
study. The Study of Tamoxifen and Raloxifene (STAR) trial,
co-ordinated by the National Surgical Adjuvant Breast and
Bowel Project, will compare tamoxifen 20mg/day with
raloxifene 60mg/day, both for 5 years; the data can be
reviewed online (http://www.breastcancerprevention.com).
Surveillance plays an important role in high risk patients,
and Giorgio Rizzatto (Ospedale Civile di Gorizia, Italy)
described the importance of ultrasound in breast cancer
while confirming that the ‘gold standard’ is still mammo-
graphy. In this context, Enrico Cassano (European Insti-
tute of Oncology) explained that the benefit to women
from mammographic screening from ages 50 to 75 years
exceeds the risk associated with radiation exposure by a
factor of almost 100 [1]. It is also important to give consid-
eration to breast density because high density can
obscure the presence of some lesions. Sylvia H Heywang-
Koebrunner (Martin-Luther University, Halle, Germany)
provided preliminary data indicating that magnetic reso-
nance imaging (MRI) can detect breast cancers that are
not visualized by mammography or ultrasound. Thus, it
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appears that MRI may allow an increase in sensitivity to in
excess of 90%. MRI promises to improve diagnosis, but
studies are needed to confirm that use of MRI confers sur-
vival advantages and to further reduce the incidence of
false-positive findings.
New technologies are always being developed, and in the
near future these will lead to improved diagnosis. An
example is the Biofield Diagnostic System (Biofield Corp.,
Alpharetta, GA, USA), which quantifies cell proliferation by
measuring electrical potentials at the skin surface. Angio-
genesis in breast tissue may be identified via infrared
imaging using the DOBI system (DOBI Medical Systems,
Mahwah, NJ, USA) and the BioLuminate Diagnostic
System (Bioluminate Inc., Dublin, CA, USA), which is a
device that aims to differentiate cancerous lesions from
normal tissue and display the information in real time on a
computer screen. These technological advances were
described by Wolfgang Gatzemeier (Fondazione S
Maugeri, Pavia, Italy).
Live surgery
Surgery was demonstrated in three different operating
theatres. Mattia Intra (European Institute of Oncology) co-
ordinated communication between the operating rooms
and the audience. In the first theatre, Professor Umberto
Veronesi showed the technique of nipple sparing mastec-
tomy plus intraoperative radiotherapy. In the other two the-
atres Drs Gennari and Galimberti demonstrated the
Radioguided Occult Lesion Localization (ROLL) tech-
nique, sentinel node biopsy (SNB) and internal mammary
node dissection.
Pathology
Following the live surgery section, Ian O Ellis (City Hospi-
tal, Nottingham, UK) outlined some important issues of
clinical relevance, including the traditional prognostic
factors. The TNM International Union Against Cancer clas-
sification fails to provide a useful tool for therapeutic deci-
sion making. Therefore, Giuseppe Viale (European
Institute of Oncology) suggested other features, such as
endocrine responsiveness or presence of special histol-
ogy findings, that may lead to modification of the current
staging system.
Sentinel node in breast cancer
According to Viviana Galimberti (European Institute of
Oncology) and to data obtained in the Milan trial, no differ-
ence exists between total axillary clearance and SNB find-
ings, indicating that the latter procedure is as effective as
the traditional method in screening for metastasis to the
axilla. However, in the International Breast Cancer Study
Group 23-01 trial (designed to determine the most appro-
priate treatment when micrometastases are present in the
lymphatic node), no significant results have yet been
obtained – the trial requires more patients. Paolo Veronesi
(European Institute of Oncology) explained the prognostic
significance of the internal mammary node, which was
complemented by a description of the role of the patholo-
gist by Donald Weaver (University of Vermont College of
Medicine, Burlington, USA) who suggested that, ideally,
the node should be sectioned into 2mm slices.
Omgo Nieweg (Antoni Leeuwenhoek Huis, Amsterdam,
The Netherlands), David Nielsen Krag (University of
Vermont College of Medicine, Burlington, USA) and
Gordon Schwartz (The Breast Health Institute, Philadel-
phia, USA) provided an overview of the implementation of
SNB, which requires complete training of a team compris-
ing surgeon, pathologist and nuclear medicine physician.
Intense training is required to accomplish effective results
and to achieve low percentages of false-positive and false-
negative cases.
Dr Jean Yves Petit (European Institute of Oncology) gave
a lecture covering the indications for nipple sparing mas-
tectomy and the importance of the tissue beneath the
nipple–areola complex (which should be approximately
2cm thick to avoid necrosis), and outlining the potential
utility of transoperative radiotherapy with a dosage of
16Gy.
Electron intraoperative therapy, targeted
intraoperative radiotherapy and bachytherapy
In the first lecture of this section, Umberto Veronesi (Euro-
pean Institute of Oncology) emphasized the importance of
immediate radiotherapy during breast conserving surgery.
The objective of intraoperative radiotherapy is to deliver
higher doses to the target area while surgically displacing
dose limiting structures. Electron intraoperative therapy
can be used not only to boost radiation dose but also to
provide a full treatment dose in a breast conserving
approach to treatment. In the literature there is no differ-
ence in results between diverse treatment trials; we were
also reminded that, although radiotherapy reduces local
recurrence by threefold (as compared with groups with no
radiotherapy), the survival rates do not differ. The Euro-
pean Institute is currently undertaking a trial in which
patients in one arm will receive postsurgical radiotherapy
at a dose of 50+10Gy and those in the other will receive
only intraoperative radiotherapy at a dose of 21Gy. No
data have yet been reported.
Roberto Orecchia (European Institute of Oncology) stated
that local recurrence after breast conserving surgery
occurs mostly in the quadrant harbouring the primary car-
cinoma. Electron intraoperative therapy is given by a
mobile linear accelerator with a robotic arm delivering
electron beams that can produce energies from 3 to
9MeV. This device can be positioned in an operating
theatre. At present, various dose levels (10–21Gy) are
being tested in early stage breast cancer patients, without278
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significant side effects [2]. Targeted intraoperative radio-
therapy is another option in this field, with acceptable
cosmetic outcome according to Jayant S Vaidya (Univer-
sity College, London, UK).
MammoSite (Proxima Therapeutics, Alpharetta, GA, USA)
is a newly developed device for brachytherapy, which
delivers an accelerated dose of radiation to a well defined
area of the breast. The indications (with respect to age,
nodal status, metastases status) are under revision. With
this device the dose administered is 34Gy but only within
1cm around the device. After application of MammoSite,
the device can be controlled by ultrasound. The device
should be removed 72 hours after the last irradiation.
Neoadjuvant therapy
Neoadjuvant therapy has been routinely administered to
women with locally advanced breast cancer since 1980.
Eric P Winer (Dana Farber Cancer Institue, Boston, USA)
suggested that new regimens and better tailoring of treat-
ment are needed, for example addition of non-cross-resis-
tant agents or biological agents. Several studies [3] have
demonstrated that preoperative and standard adjuvant
chemotherapy are equivalent with respect to disease-free
and overall survival. Also, preoperative treatments lead to
a lesser surgical procedure, and the response and biologi-
cal parameters can be monitored. Recent pilot studies
using trastuzumab in the preoperative setting have yielded
promising preliminary results [4].
The use of predictive factors allows more effective use of
available therapies by enabling clinicians to distinguish
between patients who are likely to obtain substantial
benefit from treatment and those in whom the same
therapy is less likely to be effective [3]. Thus, identification
of predictors of response is an important goal. According
to Marco Colleoni (European Institute of Oncology), the
factors that are associated with pathological complete
response were the absence of ER and progesterone
receptor expression, high grade and elevated Ki-67. Infor-
mation on endocrine responsiveness before primary sys-
temic therapy will lead to better tailoring of treatment
modalities, thus increasing the benefit of chemotherapy in
chemotherapy sensitive tumours and focusing on hor-
monal approaches in groups in which primary endocrine
therapy could be useful.
Aromatase inhibitors and beyond
Richard J Santen (University of Virginia Health System,
Charlottesville, USA) summarized the current status and
the future of aromatase inhibitors. The main difference
between tamoxifen and aromatase inhibitors lies in their
sites of action. Although tamoxifen acts by blocking cell
proliferation due to the effect of oestrogens, oestrogen
metabolites continue to exert their affects on breast cells.
On the other hand, aromatase inhibitors act by blocking
the conversion of androgens to oestrogen, avoiding the
formation of oestrogenic metabolites. The safety profile of
aromatase inhibitors differs from that of tamoxifen. Aro-
matase inhibitors increase the risk for bone loss and the
fracture rate; tamoxifen results in increased risk for
endometrial cancer and venothrombotic episodes. So, the
future of aromatase inhibitors may be in the area of breast
cancer prevention. Eric Paul Winer (Dana Farber Cancer
Institute, Boston, USA) discussed data from the Arimidex
and Tamoxifen: Alone or in Combination (ATAC) trial [5].
In that study, over a median follow-up period of
47 months, the disease-free survival was statistically differ-
ent between the groups, favouring the aromatase inhibitor
group. The only disadvantage of aromatase inhibitors is
that their long-term toxicity is unknown. Toremifene, fulves-
trant and goserelin should be studied more intensively,
according to Monica Castiglione-Gertsch (Swiss Associa-
tion of Research against Cancer/International Breast
Cancer Study Group, Bern, Switzerland).
New cytotoxic drugs
The development of new cytotoxic drugs concerns all clini-
cal oncologists. Diverse compounds have been developed
and are in phase I trials to define the maximum tolerated
dose; the next step will be phase II trials. Compounds
such as LY355703 (synthetic derivative of marine crypto-
phycins) induce mitotic arrest by binding at the micro-
tubule vinca-binding domain. Also, according to Cristiana
Sessa (Ospedale San Giovanni, Bellinzona, Switzerland),
the dosages for RPR 109881A and BMS 184476 (pacli-
taxel analogues) for evaluation in phase II trials have
already been defined. Angelo di Leo (Institut Jules Bordet,
Brussels, Belgium) indicated that the strategy for develop-
ing new cytotoxic compounds should be modified
because these agents will play a major role in endocrine
resistant disease, and this will depend on HER-2 status.
Molecular targeted compounds
The epidermal growth factor receptor family of proto-onco-
genes is known to be clinically relevant to a variety of
human malignancies. This gene family encodes four struc-
turally related transmembrane receptor tyrosine kinases,
namely HER-1, HER-2, HER-3 and HER-4. Clinical trials
of HER-1 and HER-2 inhibitors are ongoing. Combination
treatment with carboplatin, pacltaxel and trastuzumab (a
monoclonal antibody that targets cancer cells that over-
express HER-2) is well tolerated weekly, as it is with
administration every 3 weeks. According to Guiseppe
Curigliano (European Institute of Oncology, Milan, Italy),
abnormalities in growth factor signalling pathways may
account for the endocrine-resistant phenotype in breast
cancer, and may involve the activation of specific cross-
talk between ER and other pathways. There appear to be
different levels at which this cross-talk may occur, includ-
ing epidermal growth factor receptor, which may become
downregulated during endocrine treatment.279
George W Sledge (Indiana University Medical Center,
Indianapolis, USA) gave the closing lecture on the subject
of angiogenesis and antiangiogenesis. Angiogenesis plays
a central role in both local tumour growth and distant
metastasis. Thus, the inhibition of angiogenesis offers an
attractive therapeutic target with little expected toxicity.
Because of the low mutation rate of genetically stable
endothelial cells, antiangiogenic therapy was initially
thought to be ‘resistant to resistance’. However, resis-
tance mechanisms to antiangiogenic therapy have now
been identified, including endothelial cell heterogeneity
and tumour cell heterogeneity. Tumour growth (or
regrowth) may occur independent of angiogenesis.
Conclusion
Success in breast cancer management depends on the
development of new diagnostic methods, surgical treat-
ments, histopathological compliance and, of course, new
treatment options. The Milan Breast Cancer Conference
met its objective – to evaluate breast cancer with the
latest technologies in a multidisciplinary manner. It can
now be considered a reference point in breast cancer
management.
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